Inflammation, oxidative stress, and formation of advanced glycated end products (AGEs) and advanced lipoxidation end products (ALEs) are important for atherosclerosis. Vascular adhesion protein-1 (VAP-1) participates in inflammation and has semicarbazide-sensitive amine oxidase (SSAO) activity, which catalyzes oxidative deamination to produce hydrogen peroxide and aldehydes, leading to generation of AGEs and ALEs. However, the effect of VAP-1/SSAO inhibition on atherosclerosis remains controversial, and no studies used coronary angiography to evaluate if plasma VAP-1/SSAO is a biomarker for coronary artery disease (CAD). Here, we examined if plasma VAP-1/SSAO is a biomarker for CAD diagnosed by coronary angiography in humans and investigated the effect of VAP-1/SSAO inhibition by a specific inhibitor PXS-4728A on atherosclerosis in cell and animal models. In the study, VAP-1/ SSAO expression was increased in plaques in humans and in apolipoprotein E (ApoE)- 
INTRODUCTION
Atherosclerosis is the leading cause of death in developed countries. 1, 2 The World Health Organization estimated that 17.5 million people died from cardiovascular diseases, representing 31% of all global deaths. 3 Inflammation has been shown to be another important mechanism for the progression of atherosclerosis. 4, 5 Circulating leukocytes, especially monocytes, transmigrate from the vasculature to the inflammation site and are activated. Various chemokines, cytokines, enzymes, and reactive oxygen species (ROS) are produced and secreted, which may modify low-density lipoprotein (LDL), propagate inflammation, and result in atherosclerosis. Therefore, therapeutic agents able to suppress inflammation and reduce ROS in the arterial wall are of great potential as new anti-atherosclerotic drugs.
Vascular adhesion protein-1 (VAP-1) is an endothelial adhesion molecule involved in leukocyte rolling, adhesion, and transmigration into inflammatory sites. 6 VAP-1 is expressed in endothelial cells, smooth muscle cells (SMCs), and adipocytes. 7, 8 Different from other adhesion molecules, VAP-1 has an enzymatic function, called semicarbazide-sensitive amine oxidase (SSAO) (EC 1.4.3.21), which catalyzes the oxidative deamination of primary amines into aldehydes (eg, formaldehyde and methylglyoxal), hydrogen peroxide (H2O2), and ammonia. 9, 10 Under enhanced oxidative stress, aldehydes can cross-link proteins and result in the generation of advanced glycation end products (AGEs) and advanced lipoxidation end products (ALEs), both of which can induce endothelial injury and promote monocyte activation. [11] [12] [13] [14] H2O2 is a source of ROS, which can modify LDL in the arterial wall. Besides, both hydrogen peroxide and ammonia are cytotoxic to vascular cells at high concentrations. In other words, all these end products of VAP-1/SSAO can result in the development of atherosclerosis. Indeed, chronic administration of methylamine, a substrate of SSAO, has resulted in increased atheroma area in mice. 15 On the other hand, there is a soluble form of VAP-1 that can be measured in plasma. Soluble VAP-1 is derived from the transmembranous form of VAP-1 by proteolytic cleavage. [16] [17] [18] [19] Soluble VAP-1 is upregulated and released in certain inflammatory disorders, such as diabetes 20, 21 and hepatitis, 16 among others. In humans, serum VAP-1 is associated with atherosclerosis in carotid arteries 22, 23 and the incidence of major cardiovascular events. 24 Moreover, serum VAP-1 can predict cardiovascular mortality in both subjects with type 2 diabetes 25 and the general population. 24 Taken together, findings from these reports suggest that VAP-1/SSAO is involved in atherogenesis and can be a novel target for the treatment of atherosclerosis.
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Background
Vascular adhesion protein-1 (VAP-1) participates in inflammation and has semicarbazide-sensitive amine oxidase (SSAO) activity. However, the effect of VAP-1/SSAO inhibition on atherosclerosis remains controversial.
Translational Significance
Plasma VAP-1/SSAO concentrations are positively associated with the presence and the extent of coronary artery disease in humans. PXS-4728A, a specific VAP-1/SSAO inhibitor, can reduce atherosclerosis in cholesterol-fed apolipoprotein E-deficient mice, through suppression of many key steps for atherosclerosis, including reactive oxygen species generation, endothelial dysfunction, adhesion and transmigration of monocytes, recruitment and activation of macrophages, as well as migration and proliferation of smooth muscle cells. VAP-1/ SSAO inhibition is a potential treatment for atherosclerotic cardiovascular disease.
So far, there are limited studies that investigate the effects of VAP-1/SSAO inhibition on atherosclerosis. [26] [27] [28] Two of these studies used semicarbazide to inhibit VAP-1/SSAO activity in LDL receptor knockout mice, with conflicting results. In 1 report, semicarbazide aggravated atherosclerotic lesions. 27 However, semicarbazide could stabilize the established atherosclerotic lesions in another report. 26 Off-target effects of semicarbazide may be one of the reasons for the inconsistent findings, because semicarbazide is not a specific inhibitor of VAP-1/SSAO and also inhibits enzymes that are involved in atherogenesis, such as lysyl oxidase (LOX) and sphingosine-1-phosphate (S1P) lyase. [29] [30] [31] [32] [33] [34] Besides, another study using a small-molecule VAP-1 inhibitor (LJP1586) for 4 weeks did not find a significant regression of atherosclerosis. 28 However, a 4-week treatment length may not be long enough so that it may underestimate the treatment efficacy.
PXS-4728A is a highly specific inhibitor of VAP-1/ SSAO and does not have any significant off-target effects when tested against other amine oxidases or over 100 different macromolecular targets. 35 In the present study, we investigated whether VAP-1/SSAO inhibition reduced atherosclerosis using this specific inhibitor in apolipoprotein E (ApoE)-deficient mice for 15 weeks. Then, we explored the potential mechanisms in cell models. Although there were some studies that investigated the role of plasma VAP-1/SSAO as a biomarker for atherosclerosis, 21, 22, 24, 25, 36, 37 none of them used coronary angiography to confirm the presence and the extent of coronary artery disease (CAD). Therefore, we conducted a human study that examined the association of plasma VAP-1/SSAO with the presence and the extent of CAD diagnosed by coronary angiography.
MATERIALS AND METHODS
Human study. Patients. From 2008 to 2009, we conducted a cross-sectional study at National Taiwan University Hospital. 38 Subjects who were suspected to have CAD based on positive results of noninvasive stress tests and who received selective coronary angiography were invited to participate in the present study. All subjects were evaluated by cardiologists. The subjects were asked to answer questionnaires and to undergo physical examinations and blood tests with the aid of trained nurses. The choice of noninvasive stress tests, such as treadmill electrocardiography and thallium perfusion scanning, was determined by the attending physician. None of the study subjects took medications, which may affect the activity of serum SSAO or VAP-1. 39 Written informed consent was obtained from each participant. The study protocol was approved by the institutional review board, and the study was performed in accordance with the Declaration of Helsinki of Human Research.
Measurements and assays. Plasma samples were collected from each participant after overnight fasting and then stored at −80°C before the measurement of VAP-1/SSAO concentration. A standard oral 75-g glucose tolerance test was performed to measure 2-hour postprandial plasma glucose. Plasma glucose and lipid profiles were measured with an automatic analyzer (Toshiba TBA 120FR; Toshiba Medical Systems Co, Ltd, Tokyo, Japan). Plasma VAP-1/SSAO concentration was measured by a quantitative sandwich enzyme immunoassay (R&D Systems, Minneapolis, MN). The assay utilized a specific monoclonal antibody against VAP-1 as a capturer on a microplate. Detection of bound VAP-1 was performed using a different polyclonal antibody specific for VAP-1 conjugated to horseradish peroxidase. A substrate solution was added and the intensity of the color was measured, which was in proportion to the amount of plasma VAP-1 bound in the initial step. Plasma VAP-1/SSAO concentration was quantified on the basis of a reference sample of highly purified recombinant human plasma VAP-1/SSAO. The intra-assay and interassay coefficients of variation were 1.90% and 3.58%, respectively.
Definition. CAD was determined by coronary angiography and defined as the presence of at least 1 stenosis of ≥50% diameter in any of the major epicardial coronary arteries. 40 The extent of CAD was assessed based on the number of atherosclerotic segments and the number of major epicardial coronary arteries with ≥50% stenosis. Diabetes was diagnosed if fasting plasma glucose level was ≥126 mg/dL, 2-hour postprandial plasma glucose was ≥200 mg/dL, or hemoglobin A1c was ≥6.5%, or the patient used pharmacologic treatment for diabetes. 41 Hypertension was defined if systolic blood pressure was ≥140 mm Hg and diastolic blood pressure was ≥90 mm Hg, or the patient used antihypertensive drugs.
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In vivo and in vitro study. Animal groups and treatment. Male 8-week ApoE-deficient mice were purchased from Animal Resources Centre (Canning Vale, WA, Australia) and were kept under a C57/BL6 background. All procedures were performed in accordance with the local institutional guidelines for animal care of the National Taiwan University and complied with the "Guide for the Care and Use of Laboratory Animals," National Institutes of Health Publication No. 86-23, revised 2011. The protocol was approved by the National Taiwan University College of Medicine and College of Public Health Institutional Animal Care and Use Committee (IACUC NO: 20130274). The animals were randomly distributed into 5 groups: group I (control), fed with standard chow diet (n = 12); group II (cholesterol diet), fed with cholesterol-enriched diet (Purina Mills, Inc) containing 21% fat (12% saturated fat) and 0.15% cholesterol for 15 weeks (n = 12); group III (cholesterol diet and PXS-4728A, the prevention group), fed with cholesterol-enriched diet and PXS-4728A (10 mg/kg/ day in 50 µL of 5 mM Na2HPO4 solution; Pharmaxis, Australia) orally for 15 weeks (n = 12); group IV (cholesterol diet and PXS-4728A 7W, the treatment group), fed with cholesterol-enriched diet for 15 weeks and PXS-4728A (10 mg/kg/day) orally from 9 to 15 weeks (n = 12); and group V (cholesterol diet and atorvastatin, the positive therapeutic control group), fed with cholesterolenriched diet and atorvastatin (2.5 mg/kg/day, Pfizer) orally for 15 weeks (n = 12). Fasting blood samples were collected 1 day before the experiment commencement (0 time) and at the end of the experiment (after 15 weeks) for measurement of plasma triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol, glucose, creatinine, alanine transaminase, and aspartate aminotransferase (Randox Laboratories, Ltd, UK). After 15 weeks, the mice were anesthetized with pentobarbital (150 mg/kg intraperitoneally). The aortic sinus and the thoracic aorta were gently removed, and the adipose tissue was peeled off the aortic wall. Subsequently, the aortic sinus and thoracic aorta were fixed with 4% paraformaldehyde solution before cryosection.
SSAO activity analysis. SSAO activity was determined as a result of the turnover of hydrogen peroxide, which was measured by Amplex Red Monoamine Oxidase Assay Kit (A12214; Molecular Probes, Eugene, OR). Briefly, 100 µg of protein was incubated at room temperature with clorgyline 1 µM (monoamine oxidase-A inhibitor), pargyline 3 µM (monoamine oxidase-B inhibitor), benzylamine 2 mM (substrate of SSAO), Amplex Red reagent 100 µM, and horseradish peroxidase 1 U/ mL, with or without semicarbazide 1 mM. Absorbance at 570 nm was measured every 5 minutes for 30 minutes. A standard curve was plotted using different solutions with known hydrogen peroxide concentrations. The production rate of hydrogen peroxide is calculated and expressed as [H2O2]/min/µg protein. SSAO activity was determined by the difference between the production rates of hydrogen peroxide with and without semicarbazide. The linearity (R2) of this assay was 0.9989~1.0000, and the intra-or interassay coefficient of variability was 0.5%~3.8% in our laboratory.
Oil Red O staining. Atherosclerotic plaque development was quantified by histomorphometry of Oil Red O-stained aortic sinus and thoracic aorta. Staining of the aortic sinus and the thoracic aorta with Oil Red O was performed according to a standard protocol. Briefly, after being rinsed with water, the aorta was exposed to isopropanol (60%) for 2 minutes, followed by 1 hour of staining with a solution of Oil Red O dissolved in 60% isopropanol. The excess stain was removed with isopropanol and water, and the aorta was photographed using a microscope equipped with a digital camera (Leica). The Oil Red O-stained areas representing atherosclerotic plaques were measured using Image-Pro Plus. The results were expressed as the ratio of total plaque area over the total vessel area. The aortic sinus and the thoracic aorta were fixed in 4% paraformaldehyde, embedded in optimal cutting temperature, and cross-sectioned for morphometric analysis and immunohistochemistry. The aortic sinus and the thoracic aorta were cut serially into 8-µm frozen sections, and every 10th section was stained with Oil Red O for lesion area calculation. The analyses were performed microscopically; the images were analyzed with Image-Pro Plus. Western blot detection. The cells were lysed with RIPA lysis buffer (Cell Signaling, Beverly, MA). A total of 20 µg of protein was separated by 10%-12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes (Millipore, Bedford, MA). After blocking with 5% bovine serum albumin (BSA) at room temperature for 1 hour, the membranes were incubated with primary antibodies (all 1:1000 in 1.5% BSA in Tris-buffered saline with 0.2% Tween 20 (TBST)) at 4°C overnight. The membranes were then incubated with horseradish peroxidase-conjugated secondary antibodies (1:6000 in 1.5% BSA in TBST) at room temperature for 1 hour. Immunoreactivity was detected with enhanced chemiluminescence (GE Healthcare Bioscience, Piscataway, NJ).The intensities of the bands were quantified using Gel-Pro software (Media Cybernetics, Rockville, MD). β-Actin or glyceraldehyde-3-phosphate dehydrogenase was used as an internal control (1:6000 in 1.5% BSA in TBST; GeneTex, Irvine, CA). The intensities of the target proteins were normalized by the intensities of the internal control bands.
Tissue adhesion assay. The cultured U937 cells were stained with the 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester. The stained U937 cells were added to the artery for 30 minutes at 37°C. The cells were then washed and observed by fluorescence microscopy.
Cell cultures. A7r5, purchased as cryopreserved tertiary cultures (Cascade Biologics Inc, Portland, OR), was grown in Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum and 1% antibiotic/ antimycotic solution at 37°C in a 5% CO2 atmosphere. The growth medium was changed every other day until confluence, and then the cells were passaged every 3-5 days. Cells between passages 3 and 8 were used for the subsequent experiments. Before conducting experiments, A7r5 was precultured in a serum-starved medium for 24 hours. Human umbilical vein endothelial cells (HUVECs) were obtained from the Bioresource Collection and Research Center. The cells were grown in endothelial cell medium (Lonza, Walkersville, MD) containing penicillin-streptomycin (1%) and endothelial cell growth supplements at 37°C in a humidified atmosphere of 95% air and 5% CO2 and were used between passages 2 and 5. HUVEC cells overexpressing VAP-1/SSAO (HUVEC hSSAO/VAP-1 cells) and A7r5 cells overexpressing VAP-1/SSAO (A7r5 hSSAO/VAP-1 cells) were developed by Dr. Mercedes Unzeta and Dr. Montse Solé (Universitat Autònoma de Barcelona, Barcelona, Spain). The details were described in previous publications. 43, 44 HUVEC hSSAO/VAP-1 and A7r5 hSSAO/VAP-1 cells were cultured similarly ways as described for HUVEC and A7r5 cells. U937 cells were obtained from the American Type Culture Collection. Cells were grown in RPMI-1640 medium (GIBCO) supplemented with 10% fetal bovine serum, 100 units/ mL penicillin and 100 Ag/mL streptomycin at 37°C in an incubator containing 5% CO2.
ROS detection. Cells were grown in 6-cm culture dishes. After the cells were pretreated with 300 nM PXS-4728A for 1 hour, and 1 µg/mL of lipopolysaccharide (LPS) or 10 ng/mL TNF-α for another 1 hour, the cells were stained with dichlorofluorescein diacetate and then were trypsinized for FACScan cytometer (BD Biosciences, San Jose, CA) analysis.
Monocyte adhesion assay. HUVEC hSSAO/VAP-1 cells were grown in 24-well culture plates. After reaching confluence, cells were pretreated with 300 nM PXS-4728A or N-acetyl-L-cysteine (NAC) (5, 10 mM) for 1 hour, and 10 ng/mL TNF-α treatment for another 24 hours. After treatment, the U937 cells were added to the treated cells for 60 minutes at 37°C. The cells were then washed and observed under an inverted phasecontrast microscope.
Monocyte transmigration assay. HUVEC hSSAO/ VAP-1 cells were grown in transwells. After reaching confluence, the cells were pretreated with 300 nM PXS-4728A for 1 hour and were treated with 10 ng/mL TNF-α for another 24 hours. After treatment, the U937 cells were added into transwells for another 6 hours. The transmigrated cells were determined after 6 hours by Coomassie blue staining and count.
Cell cycle analysis. A7r5 hSSAO/VAP-1 cells were grown in 6-well culture plates and then serum-starved as described earlier. After pretreatment with 300 nM PXS-4728A or NAC (1, 2 mM) for 1 hour and with 20 ng/ mL platelet-derived growth factor (PDGF)-BB for another 24 hours, the cells were trypsinized and stained with propidium iodide. The cell-cycle progression was detected on a FACScan cytometer (BD Biosciences) and was analyzed by ModFit software.
Wound-healing assay. A7r5 hSSAO/VAP-1 cells were grown in 6 cm culture dishes. After the cells were pretreated with 300 nM PXS-4728A or NAC (1, 2 mM) for 1 hour, wounds were inflicted by dragging a sterile pipette tip across the monolayer, creating a 250-µm cell-free path, after which 20 ng/mL PDGF-BB (Peprotech, Rocky Hill, NJ) was added. After 24 hours, the migration rate of the cells and the wound closure area-to-original wound area ratio were calculated using a real-time cultured cell monitoring system (ASTEC, Japan) and Metamorph and Image-Pro Plus 4.5 software.
Statistical analyses. Continuous variables with normal distribution were presented as means ± standard deviation or means ± standard error of the mean. Variables with skewed distribution were presented as medians (interquartile ranges) and were analyzed after logarithmic transformation. The statistical significance of the differences in different subgroups was tested with Student t test or χ 2 test. Unadjusted Pearson correlation coefficients and partial correlation coefficients adjusting for age and gender were used to determine the relationship of plasma VAP-1/SSAO with cardiovascular risk factors, the number of vessels with stenosis, and the number of segments with stenosis. The association between CAD and plasma VAP-1/SSAO was evaluated by logistic regression, whereas the association between the number of vessels with stenosis, the number of segments with stenosis, and plasma VAP-1/SSAO was evaluated by linear regression analyses. Clinically important variables associated with CAD were included in multivariate analyses, including age, gender, hypertension, diabetes, smoking, and LDL-C. A 2-tailed P-value below 0.05 was considered significant. Stata/SE 14.0 for Windows (StataCorp LP, College Station, TX) was used for statistical analyses.
RESULTS

Expression of VAP-1/SSAO in atherosclerotic lesions in
human and ApoE-deficient mice. To examine VAP-1/ SSAO expression during atherosclerosis in humans and mice, immunohistochemical staining was performed with antibodies against VAP-1/SSAO. In the human normal coronary artery, little VAP-1/SSAO expression was seen (Fig 1, A) . Compared with normal artery, VAP-1/ SSAO expression was significantly stronger in the atherosclerotic plaques. To examine the cellular localization of VAP-1/SSAO during the formation of atherosclerosis in humans and in ApoE-deficient mice, immunohistochemical staining with antibodies against VAP-1/SSAO, endothelial cells, or SMCs was carried out in the human coronary artery and the mice aorta sections (Fig 1, A and B) . VAP-1/SSAO staining overlaid with markers staining for endothelial cells and SMC (Fig 1, A and B) , thus confirming that endothelial cells and SMCs in atherosclerotic plaques express VAP-1/ SSAO. In Supplementary Fig S1, VAP-1/SSAO expression in the thoracic aorta increased by time after cholesterol-enriched diet was given. However, there was no significant difference in plasma VAP-1/SSAO concentrations at different times after cholesterol-enriched diet was given (means ± standard deviations: at day 0, 1.007 ± 0.7418 ng/mL; at the 9th week, 1.972 ± 1.726 ng/ mL; at the 12th week, 3.276 ± 2.330 ng/mL; at the 15th week, 1.639 ± 0.613 ng/mL; P > 0.05).
Plasma VAP-1/SSAO concentrations are positively associated with the presence and the extent of CAD in humans. The baseline characteristics of the subjects enrolled in the human study are shown in Table I . A total of 127 (70%) subjects were diagnosed with CAD. Compared with those without CAD, subjects with CAD were more likely to be male, had a higher prevalence to use statins, and had lower plasma high-density lipoprotein cholesterol. There were no significant differences between the 2 groups regarding age, smoking, body mass index, blood pressure, history of hypertension or diabetes, plasma concentrations of fasting and 2-hour postprandial glucose, hemoglobin A1c, total cholesterol, triglyceride, and LDL-C. Notably, plasma VAP-1/SSAO concentrations were significantly higher in subjects with CAD than in the control group (median 579 [interquartile range 490-710] ng/mL vs 544 [460-644] ng/mL, P = 0.003; Table I and Fig 2, A) . There was a positive association between plasma VAP-1/SSAO concentrations, the number of coronary arteries with stenosis (P for trend <0.001; Fig 2,  B) , and the number of coronary arterial segments with stenosis (P for trend = 0.001; Fig 2, C) . Table II shows the relationships between plasma VAP-1/SSAO concentrations and clinical characteristics. In univariate analysis, plasma VAP-1/SSAO positively correlated with age (r = 0.1485, P = 0.047), fasting plasma glucose (r = 0.2349, P = 0.0015), 2-hour postprandial plasma glucose (r = 0.3435, P < 0.0001), the number of coronary arteries with stenosis (r = 0.2569, P = 0.0005), and the number of coronary arterial segments with stenosis (r = 0.2505, P = 0.0007). The relationships remained significant after controlling for age and gender. There was a significant correlation between plasma VAP-1/SSAO and plasma triglyceride concentrations (r = 0.1731, P = 0.021), adjusted for age and gender. Besides, plasma VAP-1/SSAO concentrations were similar between subjects receiving statins and subjects who did not receive statins (median 570 [interquartile range 475-674] ng/ mL vs 578 [489-652] ng/mL, P = 0.99).
To determine whether plasma VAP-1/SSAO was an independent predictor of the presence and the extent of CAD, we performed logistic and linear regression analyses Expression of VAP-1 is increased in atherosclerotic plaques and is colocalized with ECs and SMCs. Immunohistochemical staining with the antibodies against EC, SMC, and VAP-1 by double immunofluorescent staining in (A) coronary artery sections in humans (n = 3-4) and in (B) aorta sections in apolipoprotein E-deficient mice (n = 3-4). VAP-1 staining (white arrows) is stronger in atherosclerotic plaques than in normal parts in the human aorta. VAP-1 staining is colocalized with EC and SMC. Scale bar = 100 µm in (A) and 50 µm in (B). Nuclei are stained with 4′,6-diamidino-2-phenylindole. Dashed white lines represent internal elastic lamina. VAP-1, vascular adhesion protein-1; EC, endothelial cell; SMC, smooth muscle cell. (Table III) . Plasma VAP-1/SSAO concentrations were associated with the presence of CAD (odds ratio = 2.09, 95% confidence interval 1.29-3.38, P = 0.003, adjusted for age and gender). There was a positive association between plasma VAP-1/SSAO concentrations and the extent of CAD, as measured by the number of coronary arteries with stenosis (β = 0.32, P < 0.001) and the number of coronary arterial segments with stenosis (β = 0.62, P < 0.001). The relationship of plasma VAP-1/SSAO concentrations with the presence and the extent of CAD remained significant after further adjustment for history of hypertension, diabetes, plasma LDL-C, and smoking.
PXS-4728A inhibits VAP-1/SSAO activity and the consequent H2O2 generation and oxidative stress in cholesterol-
fed ApoE-deficient mice. To detect the effects of PXS-4728A treatment on VAP-1/SSAO activity, we measured SSAO-specific H2O2 production rate in cholesterolfed ApoE-deficient mice. PXS-4728A significantly inhibited VAP-1/SSAO activity and SSAO-specific H2O2 production in thoracic aortic tissues, the lung, and epididymal fat (Fig 3, A-C) . The oxidative stress expression was determined by nitrotyrosine staining. The result showed that the oxidative stress expression was decreased significantly by PXS-4728A treatment (Fig 3, D) .
SSAO inhibition by PXS-4728A reduces atherosclerosis in
cholesterol-fed ApoE-deficient mice. The effects of PXS-4728A on the atherosclerotic plaque area were quantified by histomorphometric analysis of the aortic sinus and thoracic aortic sections in ApoE-deficient mice 15 weeks after cholesterol-enriched diet. The atherosclerotic plaque area was determined by Oil Red O staining analysis (Fig 3, E and F) . The ratios of atherosclerotic plaque area to total area of the aortic sinus and thoracic aorta were significantly higher in the cholesterol-fed group than in the control group. Compared with the cholesterolfed group, PXS-4728A significantly reduced the ratio of the atherosclerotic plaque area to the total area both in the prevention group and in the treatment group (51.69% ± 2.27% in the cholesterol-fed group; 36.05% ± 3.93% in the prevention group [PXS-4728A given, along with cholesterol-enriched diet for 15 weeks], P < 0.05, vs the cholesterol-fed group; and 36.65% ± 4.29% in the treatment group [cholesterolenriched diet was given for 8 weeks followed by cholesterol-enriched diet plus PXS-4728A for another 7 weeks, the PXS-4728A 7W group], P < 0.05, vs the cholesterol-fed group). Similar data were observed in the ratios of the atherosclerotic plaque area to the total area of thoracic aorta. Importantly, the effect of VAP-1/ SSAO inhibition in the prevention group was similar to the effect of atorvastatin (2.5 mg/kg/day for 15 weeks), the treatment of choice for primary and secondary preventions for cardiovascular diseases in humans.
Effects of VAP-1/SSAO inhibition by PXS-4728A on serum biochemical parameters of cholesterol-fed ApoE-deficient mice. As shown in Table IV , plasma total cholesterol, LDL-C, triglyceride, and glucose concentrations were significantly increased in the cholesterol-fed group compared with the control group (P < 0.05). The elevations of plasma total cholesterol, LDL-C, and glucose concentrations were significantly reduced by PXS-4728A (the prevention group) or atorvastatin (all P < 0.05). In the PXS-4728A 7W group (the treatment group), plasma glucose concentrations decreased significantly, but plasma total cholesterol and LDL-C were not significantly different from those in the cholesterol-fed group. In all groups, there was no significant difference in plasma creatinine, aspartate aminotransferase, and alanine transaminase.
SSAO inhibition by PXS-4728A reduces the expression of adhesion molecules and inflammatory cytokines in atherosclerotic plaques. To test the effects of PXS-4728A on inflammation, immunohistochemical staining and Western blot with antibodies against adhesion molecules and inflammatory cytokines were carried out on thoracic aorta sections. The expression of adhesion molecules, including VAP-1, vascular cell adhesion molecule-1, ICAM-1, and E-selectin, was higher in the thoracic aorta of ApoE-deficient mice in the cholesterol-fed group than in the control group (Fig 4, A, . The values are the mean ± standard error of the mean. *P < 0.05. CTRL, cholesterol-fed, cholesterolenriched diet for 15 weeks; cholesterol-fed/PXS, PXS (10 mg/kg/day) was given, along with cholesterolenriched diet for 15 weeks, "the prevention group"; cholesterol-fed/PXS 7W, cholesterol-enriched diet was given for 8 weeks followed by cholesterol-enriched diet plus PXS (10 mg/kg/day) for another 7 weeks, "the treatment group"; cholesterol-fed/atorvastatin, atorvastatin (2.5 mg/kg/day) was given, along with cholesterol-enriched diet for 15 weeks, " the positive therapeutic control group." SSAO, semicarbazide-sensitive amine oxidase; CTRL, control group; PXS, PXS-4728A. Fig S2) . VAP-1/SSAO inhibition by PXS-4728A (both the prevention and the treatment groups) significantly decreased the expression of these adhesion molecules in cholesterol-fed mice (Fig 4, A, and Supplementary  Fig S2) .
As leukocyte recruitment plays an important role in the initiation and progression of atherosclerosis, 4,5 we used labeled-U937 cells to directly test whether VAP-1/SSAO inhibition can inhibit early monocyte recruitment into atherosclerotic lesions. In Fig 4, B and C, the number of labeled-U937 cells on the artery was higher in the cholesterol-fed group than in the control group (Fig 4, B  and C) . PXS-4728A (both in the prevention and the treatment groups) significantly decreased the number of monocytes that adhered to the arteries, compared with the number in the cholesterol-fed group. In Fig 4, D, and in Supplementary Fig S2, the expressions of proinflammatory molecules TNF-α and MCP-1 were higher in the cholesterol-fed group and were reduced by PXS-4728A (both in the prevention and the treatment groups). All together, the results suggest that VAP-1/ SSAO inhibition by PXS-4728A reduces inflammation and leukocyte recruitment to atherosclerotic lesions in cholesterol-fed ApoE-deficient mice.
SSAO inhibition by PXS-4728A reduces the expression of markers for macrophage recruitment and activation in atherosclerotic plaques. TLR-4, CD36, and LOX-1 activations by oxidized low-density lipoprotein (oxLDL) contribute to the pathogenesis of atherosclerosis. 45 During the development of atherosclerosis, macrophages are recruited to plaques, where they are activated by AGEs and oxLDL. 46 Activated macrophages form foam cells, which consequently propagate inflammation and progress to atherosclerosis. 47, 48 To test the effect of VAP-1/SSAO inhibition by PXS-4728A on AGEs-LDL-activated macrophages in the atherosclerotic plaques, immunohistochemical staining and Western blot with antibodies against Iba-1 (a macrophage marker), TLR-4, CD36, RAGE, and LOX-1 were performed in ApoE-deficient mice thoracic aorta sections. As shown in Fig 4, E, and Supplementary Fig S2, the cholesterol-enriched diet resulted in a significant increase in the recruitment of 
Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; CTRL, control group; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PXS, PXS-4728A. Means ± standard errors of the mean are shown. CTRL, cholesterol-fed, cholesterol-enriched diet for 15 weeks; cholesterol-fed/PXS, PXS was given, along with cholesterol-enriched diet for 15 weeks; cholesterol-fed/PXS 7W, cholesterol-enriched diet was given for 8 weeks followed by cholesterol-enriched diet plus PXS for another 7 weeks; cholesterol-fed/atorvastatin, atorvastatin was given, along with cholesterol-enriched diet for 15 weeks. *P < 0.05 compared with the CTRL. † P < 0.05 compared with the cholesterol-fed group.
macrophages and the expression of TLR-4, CD36, RAGE, and LOX-1 in the atherosclerotic plaques. These effects were markedly decreased by PXS-4728A, except CD36 and LOX-1 expression in the cholesterol-fed/PXS7W group. All together, these data showed that VAP-1/ SSAO inhibition by PXS-4728A reduces the expression of markers for macrophage recruitment and activation in atherosclerotic plaques.
SSAO inhibition by PXS-4728A reduces the adhesion and the transmigration of monocytes in TNF-α-treated
HUVEC overexpressing hSSAO/VAP-1 by inhibiting ROS production. To elucidate the role of VAP-1/SSAO in endothelial cells on atherosclerosis, HUVEC hSSAO/ VAP-1 cells were used. In Fig 5, A and B , HUVEC hSSAO/VAP-1 cells expressed more VAP-1/SSAO protein than HUVEC, as determined by Western blot and immunofluorescence analysis. The VAP-1/SSAO activity of HUVEC hSSAO/VAP-1 cells was inhibited completely by PXS-4728A treatment (Fig 5, C) .
As TNF-α-induced endothelial dysfunction and ROS production play a pivotal role in the pathogenesis of atherosclerosis, 49 the effect of VAP-1/SSAO inhibition was also tested in the presence of TNF-α stimulation. As shown in Fig 5, D , the accumulation of intracellular ROS was increased by TNF-α treatment, and the increased effect was significantly inhibited by PXS-4728A treatment, suggesting that VAP-1/SSAO inhibition can reduce TNF-α-induced ROS production. During inflammation, monocytes adhered to the vascular wall and then transmigrated into subendothelial space. 50 Therefore, we evaluated the effect of VAP-1/SSAO inhibition on the adhesion and transmigration of monocytes. As shown in Fig 5, E and F, the number of adhered or transmigrated monocytes were increased by TNF-α treatment. PXS-4728A pretreatment significantly reduced the number of monocytes that adhered to or transmigrated across TNF-α-treated HUVEC hSSAO/VAP-1 cells. Besides, pretreatment with NAC, a ROS scavenger, also reduced the number of adhered or transmigrated monocytes. Taken together, these findings suggest that VAP-1/SSAO inhibition by PXS-4728A reduced the adhesion and transmigration of monocytes in TNF-α-treated HUVEC hSSAO/VAP-1 cells by inhibiting the production of ROS.
SSAO inhibition by PXS-4728A reduces the expression of MMP-9, SMC, and PCNA in atherosclerotic plaques. The proliferation and the migration of vascular SMC play an important role in the progression of atherosclerosis. SMCs migrate from the tunica media into the intima via degradation of the extracellular matrix mediated by MMP-9 and other proteinases. 51, 52 In Fig 4, F, and Supplementary Fig S2, analysis of MMP-9 and the SMC marker, α-actin, revealed stronger MMP-9 expression and more α-actin-positive cells in the thickened intima of the cholesterol-fed group compared with the intima of the control group. These effects were significantly reduced by PXS-4728A treatment. To detect cell proliferation in the atherosclerotic plaque, PCNA staining was used. As shown in Fig 4, F , and in Supplementary Fig S2, the expression and the number of PCNA-positive cells in the thickened plaques were higher in the cholesterol-fed group than in the control group and the PXS-4728A groups. Taken together, these findings suggest that VAP-1/ SSAO inhibition by PXS-4728A reduces the expression of markers for SMC migration and proliferation in the development of atherosclerosis. Semicarbazide-sensitive amine oxidase inhibition by PXS suppresses expression of adhesion molecules, inflammatory cytokines, markers for macrophage recruitment and activation, as well as markers for SMC migration and proliferation in apolipoprotein E (ApoE)-deficient mice. A, Expression of adhesion molecules, including VAP-1, VCAM-1, ICAM-1, and E-selectin in the atherosclerotic plaques by immunohistochemical staining in different groups. The negative control containing only a rhodamine-conjugated secondary antibody without primary antibody incubation (without 1°primary antibody) showed the species specificity of the antibody. B, En face microscopy images illustrate BCECF-AM-labeled U937 bound to the endothelium of the thoracic aorta. C, Quantification of the number of monocytes adhered to aorta in different groups, represented as the percentage of control. The values are the mean ± standard error of the mean (n = 3-5 per group), *P < 0.05. D, Expression of inflammatory cytokines, including MCP-1 and TNF-α in the atherosclerotic plaques by immunohistochemical staining in different groups. E, Expression of markers for macrophage recruitment and activation, including Iba-1 (macrophage), TLR-4, CD36, RAGE, and LOX-1 in the atherosclerotic plaques by immunohistochemical staining in different groups. F, Expression of MMP-9, SMC, and PCNA in the atherosclerotic plaques by immunohistochemical staining in different groups. The internal elastic lamina is indicated by the arrowheads. The negative control containing only a rhodamine-or FITC-conjugated secondary antibody without primary antibody incubation (without 1°primary antibody) showed the species specificity of the antibody. Scale bar = 100 µm. CTRL, cholesterol-fed, cholesterolenriched diet for 15 weeks; cholesterol-fed/PXS, PXS was given, along with cholesterol-enriched diet for 15 weeks; cholesterol-fed/PXS 7W, cholesterol-enriched diet was given for 8 weeks followed by cholesterol-enriched diet plus PXS for another 7 weeks. CTRL, control group; VAP-1, vascular adhesion protein-1; ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; BCECF-AM, 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester; TLR-4, Toll-like receptor-4; RAGE, receptor for advanced glycation end product; LOX-1, lectin-like oxidized low-density lipoprotein receptor-1; MMP-9, matrix metalloproteinase-9; PCNA, proliferative cell nuclear antigen; FITC, fluorescein isothiocyanate; SMC, smooth muscle cell; MCP-1, monocyte chemoattractant protein-1; TNF-α, tumor necrosis factor alpha; PXS, PXS-4728A.
Fig 5.
SSAO inhibition by PXS reduces reactive oxygen species production and monocyte transmigration in TNF-α-induced HUVECs overexpressing SSAO/VAP-1 (HUVEC hSSAO/VAP-1 cells). A-C, VAP-1 expression and SSAO activity were determined by Western blot, immunofluorescence, and SSAO activity assay in HUVEC and HUVEC hSSAO/VAP-1 cells. D, Cells were pretreated with PXS (300 nM) for 1 hour and then treated with TNF-α (10 ng/mL) for another 1 hour. After treatment, the cells were then loaded with reactive oxygen species indicator dichlorofluorescein diacetate, and the fluorescence intensity was assessed by flow cytometry and quantified. E, Smooth muscle cells were pretreated with PXS (300 nM) or NAC (5, 10 mM) for 1 hour and then treated with 10 ng/mL TNF-α for another 24 hours. The monocyte adhesion assay was used to evaluate the dysfunction of TNF-α-treated HUVEC hSSAO/VAP-1 cells. F, Cells were pretreated with PXS (300 nM) or NAC (5, 10 mM) for 1 hour and then treated with TNF-α (10 ng/mL) for another 24 hours. After treatment, monocytes were added in the upper well. Monocytes transmigrated for 6 hours onto the lower surface of the filter and were stained with Coomassie blue and counted. The bar graphs represent the numbers of cells that transmigrated. The values are the mean ± standard error of the mean (n = 3-6 per group). *P < 0.05. Scale bar = 100 µm. CTRL, control; PXS, PXS-4728A; VAP-1, vascular adhesion protein-1; HUVEC, human umbilical vein endothelial cells; HUVEC hSSAO/ VAP-1 cells, HUVEC cells overexpressing VAP-1/SSAO; SSAO, semicarbazide-sensitive amine oxidase; NAC, N-acetyl-L-cysteine; TNF-α, tumor necrosis factor alpha; DCF, 2′,7′-dichlorodihydrofluorescein diacetate; GADPH, glyceraldehyde-3-phosphate dehydrogenase. (Fig 6, C) .
SSAO inhibition by PXS-
ROS have been reported to accelerate the proliferation and the migration of vascular SMC. 53 As shown in First, we measured the effects of PXS-4728A on SMC proliferation by flow cytometry. As shown in Fig 6 , E, after PDGF-BB stimulation, the proportion of A7r5 hSSAO/VAP-1 cells in the S phase increased from 7.72 ± 0.43% to 12.79 ± 0.65% (P < 0.05), which was prevented by PXS-4728A pretreatment (12.79 ± 0.65% vs . A-C, VAP-1 expression and SSAO activity were determined by Western blot, immunofluorescence, and SSAO activity assay in A7r5 smooth muscle cells andA7r5 hSSAO/VAP-1 cells. D, Cells were pretreated with PXS (300 nM) for 1 hour and then treated with LPS (1 µg/mL) for another 1 hour. After treatment, the cells were loaded with reactive oxygen species indicator dichlorofluorescein diacetate, and fluorescence intensity was assessed by flow cytometry and quantified. E, Cells were left untreated or were treated with 300 nM PXS or NAC (1, 2 mM) for 1 hour and then with PDGF-BB for an additional 24 hours. The proportion of cells in the S phase was determined by FACScan analysis. F, Cell migration was examined via wound-healing assay. The migration rate of the cells was determined. The values are the mean ± standard error of the mean (n = 3-5 per group). *P < 0.05. Scale bar = 100 µm. CTRL, control; PXS, PXS-4728A; VAP-1, vascular adhesion protein-1; A7r5 hSSAO/VAP-1 cells, A7r5 cells overexpressing VAP-1/SSAO; SSAO, semicarbazide-sensitive amine oxidase; LPS, lipopolysaccharide; NAC, N-acetyl-L-cysteine; PDGF, platelet-derived growth factor; DCF, 2′,7′-dichlorodihydrofluorescein diacetate; GADPH, glyceraldehyde-3-phosphate dehydrogenase.
8.45 ± 0.25%, P < 0.05) and accompanied by a significant increase in the proportion of cells in the G0-G1 phase (from 73.33 ± 2.19% to 78.05 ± 1.33%, P < 0.05). These data indicate that PXS-4728A suppresses the proliferation of PDGF-BB-treated A7r5 hSSAO/VAP-1 cells via G0-G1 arrest. Besides, pretreatment with ROS scavenger NAC also reduced PDGF-BB-stimulated proliferation of A7r5 hSSAO/VAP-1 cells. For SMC migration, woundhealing assays were done. As shown in Fig 6, F , the migration of A7r5 hSSAO/VAP-1 cells increased significantly after stimulation with PDGF-BB. PXS-4728A or NAC treatment reduced the migration rate of PDGF-BB-treated A7r5 hSSAO/VAP-1 cells significantly. Taken together, these findings indicate that VAP-1/SSAO inhibition by PXS-4728A reduces the proliferation and the migration of PDGF-BB-treated A7r5 hSSAO/VAP-1 cells by inhibiting ROS production.
DISCUSSION
In the present study, we have demonstrated that plasma VAP-1/SSAO concentrations were higher in subjects with CAD and were positively associated with the number of coronary arteries or coronary arterial segments with stenosis in humans. The findings are different from the results in a study by Salmi et al, 37 who did not find any significant association between serum VAP-1/SSAO and CAD. Because the diagnosis of CAD in the study was established by self-reporting and verified with drug reimbursement records, but not by coronary angiography as in the present study, the possible ascertainment bias may reduce the statistical power. Aside from CAD, there are several articles that report a significant relationship between serum VAP-1/SSAO and atherosclerosis in carotid arteries in humans. Serum VAP-1/SSAO activity has been reported to be associated with carotid intimamedial thickness and plaques in women 22 and in subjects with diabetes. 36 In the general population, we have demonstrated that acute change of serum VAP-1/SSAO to hyperglycemia was correlated to blood AGE concentrations and carotid intima-medial thickness. 23 Furthermore, we have reported that serum VAP-1/SSAO can predict cardiovascular mortality and all-cause mortality in subjects with diabetes, 25 whereas in subjects older than 50 years, a Finnish study has shown that serum VAP-1/ SSAO can predict the incidence of major cardiovascular events and cardiovascular mortality. 24 All these results suggest that blood VAP-1/SSAO is a biomarker for atherosclerosis and can be used to predict cardiovascular events and mortality.
A recent study supports our findings that endothelial cells in atherosclerotic plaques displayed increased VAP-1 expression compared with normal artery, and VAP-1/ SSAO inhibition reduced the macrophage recruitment in atherosclerotic plaques. 28 In LDL receptor-deficient mice expressing only apolipoprotein B100 (LDLR -/-ApoB 100/100 ), VAP-1 was expressed on the luminal surface of endothelial cells in atherosclerotic plaques. However, endothelial cells lining the nonatherosclerotic vessel wall were VAP-1 negative. A small molecular VAP-1 inhibitor (LJP1586) given after introducing high-fat diet for 8 weeks reduced the density of macrophages in plaques. In contrast with our study, there was no significant difference in the size of plaques after LJP1586 treatment for 4 weeks. This discrepancy may be explained by a shorter treatment length (4 weeks), which may not be long enough to observe the significant regression of atherosclerosis. Besides, mice were shifted to a normal chow diet during LJP1586 treatment, which may slow down the progression of atherosclerosis. Therefore, the effect of LJP1586 on atherosclerosis was minimized, so that no significant difference in the size of plaques was found between the treatment and the control groups.
RAGE is a member of the immunoglobulin superfamily that is able to bind diverse molecules such as AGEs, ALEs, and high-mobility group box 1, and to function as a signaling transduction receptor. 55 The interaction of RAGE and its ligands can induce the release of inflammatory cytokines, increase expressions of adhesion molecules, and promote SMC proliferation, thereby contributing to atherogenesis. 56 RAGE inactivation has been shown to inhibit atherosclerosis through reducing oxLDLinduced proinflammatory responses and oxidative stress in LDL receptor-deficient mice. 57 In the present study, VAP-1/SSAO inhibition decreased H2O2 production and the expression of RAGE in the vessel walls, suggesting 2 possible mechanisms whereby VAP-1/SSAO inhibition reduces atherosclerosis.
In the present study, plasma VAP-1/SSAO concentrations correlated positively with plasma fasting glucose and 2-hour postprandial glucose in humans (Table II) , and VAP-1/SSAO inhibition by PXS-4728A significantly lowered fasting plasma glucose in ApoE-deficient mice (Table IV) . In the literature, serum VAP-1/SSAO activity has been reported to correlate with plasma glucose concentrations in humans. 20, 21, 37 Besides, a population study found an association of serum VAP-1/SSAO activity with type 1 diabetes in both genders and with type 2 diabetes in men. 22 There are 2 possible mechanisms linking VAP-1/SSAO and glucose homeostasis. First, vascular VAP-1/SSAO participates in inflammation of adipose tissue. Adipose macrophages can secrete various cytokines, such as TNFα, interleukin-1β, and interferon-γ, which results in insulin resistance in adipose tissue and promotes lipolysis. 58 Increased circulating fatty acids may lead to ectopic lipid accumulation and insulin resistance in the liver and the skeletal muscle through the generation of diacylglyceride and protein kinase C. In VAP-1/SSAO knockout mice, leukocyte infiltration in adipose tissue was reduced. 59 Besides, these mice had an increased fat mass, suggesting that their fat storage capacity was increased and may be more resistant to insulin resistance resulting from ectopic lipid accumulation. In contrast, adipose VAP-1/SSAO may play a beneficial role by enhancing glucose uptake induced by amines, which has been shown in the experiments using fat cells from VAP-1/SSAO knockout mice 43 and in KKAy mice using another SSAO inhibitor (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (FPFA). 60 In KKAy mice, a single injection of FPFA resulted in an elevation of plasma glucose. However, chronic treatment of FPFA on glucose homeostasis was not evaluated in the study. Taken together, because inhibition of adipose inflammation may take a longer time to develop, we hypothesize that VAP-1/SSAO inhibition may increase plasma glucose concentrations through the inhibition of adipose glucose uptake in a short period of time but may improve glucose homeostasis through the reduction of adipose inflammation in a long period of time, as shown in the present study. Further studies are needed to prove the hypothesis in the future.
Hypercholesterolemia is an important risk factor for atherosclerosis. In humans, serum VAP-1/SSAO activity has been reported to correlate with plasma LDL-C 22 and total cholesterol. 61 In the present study, VAP-1/ SSAO inhibition by PXS-4728A for 15 weeks significantly reduced plasma LDL-C levels in cholesterolfed ApoE-deficient mice. However, plasma LDL-C levels were not significantly suppressed with PXS-4728A for 7 weeks, suggesting that treatment duration is an important factor for plasma LDL-C reduction. Indeed, inhibition of VAP-1/SSAO by another specific inhibitor LJP1586 for 4 weeks failed to show any change in plasma LDL-C in LDLR −/− ApoB 100/100 mice. 28 The mechanism for the effect remains unknown. Several proinflammatory cytokines and stimulants, such as TNFα, IL-1, and LPS, have been reported to increase serum cholesterol levels by enhancing hepatic cholesterol synthesis and 3-hydroxy-3-methylglutaryl-CoA reductase activity and reducing bile acid synthesis in rodent models. 62 However, in humans, subjects with inflammatory diseases, such as rheumatoid arthritis and psoriasis, have lower levels of plasma LDL-C, which can be elevated by anti-inflammatory agents. 63, 64 In these patients, there are changes in the quality of LDL-C, such as generation of small dense LDLs and increased susceptibility toward oxidation. 62 Therefore, these patients have an increased risk of atherosclerosis despite lower plasma LDL-C levels. Further studies are needed to clarify the mechanisms on how VAP-1/SSAO inhibition reduces plasma LDL-C, considering the treatment duration and differences in research models. Clinically, statins are the treatment of choice for primary and secondary preventions of cardiovascular events, mainly through the reduction in plasma LDL-C. 65, 66 However, concerns about the association between statins and new-onset diabetes have recently been raised. In the present study, VAP-1/ SSAO inhibition has been shown to successfully reduce plaque size, and the efficacy of VAP-1/SSAO inhibition for primary prevention of atherosclerosis is comparable with that of atorvastatin. Because PXS-4728A for 7 weeks reduced plaque size without a significant decrease in plasma LDL-C levels, this suggests that VAP-1/SSAO inhibition can alleviate the progression of atherosclerosis through lipid-independent mechanisms, such as decreasing ROS production, lowering plasma glucose, suppressing endothelial activation, inhibiting recruitment and activation of macrophages, and attenuating migration and proliferation of SMC. Taken together, our findings suggest that VAP-1/SSAO inhibition is a novel method for the treatment of atherosclerosis with mechanisms different from those of statins.
The first step to initiate atherosclerosis is the activation of endothelial cells, which facilitates leukocyte trafficking to inflammatory sites, thereby kicking off the downstream pathologic immune response. Therefore, the role of VAP-1/SSAO on endothelial cells serves as a crucial cornerstone for the antiatherosclerotic effects of PXS-4728A. VAP-1/SSAO on endothelial cells not only serves as an adhesion molecule 6 but also acts as an ectoenzyme contributing to leukocyte rolling, firm adhesion, and transmigration. [67] [68] [69] [70] A working model has been proposed to explain how VAP-1/SSAO modulates the leukocyte extravasation cascade, based on study results using anti-VAP-1 antibodies and VAP-1/SSAO inhibitors and HUVEC transfected with an enzyme-inactive mutant of VAP-1. 10 First, VAP-1 on endothelial cells serves as an adhesin to interact with leukocytes through antibodydefined epitopes. Then, the leukocyte surface molecule is used as a substrate for oxidative deamination reaction of SSAO. This leads to the formation of a transient covalent interaction (Schiff base) that brings endothelial cells and leukocytes together. Finally, after the enzyme reaction proceeds, the leukocyte surface molecule is catalyzed to aldehyde and H2O2, which can serve as a signaling molecule to regulate leukocyte emigration and modify inflammatory cascades in the local microenvironment. In the present study, VAP-1/SSAO inhibition reduced monocyte adhesion to aorta (Fig 4, B and C) , as well as adhesion to and transmigration through HUVEC hSSAO/ VAP-1 monolayers (Fig 5, E and F) . Our results indicate that abrogation of VAP-1/SSAO activity inhibits a sequential process associated with endothelial activation. First, VAP-1/SSAO inhibition reduced the expressions of E-selectin, P-selectin, and ICAM-1 on aorta (Fig 4, A, and Supplementary Fig S2) , which supports the concept that the catalytic activity of VAP-1/SSAO can upregulate several other endothelial adhesion molecules. 71, 72 Notably, we found that inhibition of VAP-1/SSAO activity also reduced its own protein expression on endothelial cells (Fig 4, A, and Supplementary Fig S2) . This finding implies that there might be a positive feedback mechanism by which VAP-1/SSAO activity could regulate its own protein expression, but further studies are warranted to prove this hypothesis. Moreover, we found that VAP-1/SSAO inhibition suppressed intracellular ROS production in HUVEC hSSAO/VAP-1 cells (Fig 5, D) . In the literature, intracellular ROS have been shown to regulate the expression of adhesion molecules. 73, 74 In addition, we have proven that the number of adhered and transmigrated monocytes was decreased by antioxidant NAC (Fig 5, E  and F) . Taken together, our results suggest that VAP-1/ SSAO inhibition can reduce monocyte adhesion and transmigration, which may result from a direct enzymatic effect, suppressed intracellular ROS production, and reduced expression of adhesion molecules.
During inflammation, chemotactic proteins such as MCP-1 are released to recruit leukocytes, especially monocytes, into the inflammatory site. 4 Once monocytes have migrated into the intima, they can be stimulated by various cytokines and differentiate into macrophages. In the present study, cholesterol-enriched diet resulted in the upregulation of the expression of MCP-1 and various proinflammatory cytokines, and more macrophages were recruited in the atherosclerotic plaques. By contrast, VAP-1/SSAO inhibition reduced the expression of MCP-1 and these cytokines and suppressed macrophage recruitment. These findings are in agreement with previous reports. 72, 75 In a rat model, VAP-1/ SSAO inhibition has been shown to suppress the expression of MCP-1 and TNF-α, resulting in reduced choroidal neovascularization. 75 Similarly, decreased expression of MCP-1 and TNF-α by VAP-1/SSAO inhibition has also been demonstrated in a mice model of intracerebral hemorrhagic stroke. 72 Proliferation and migration of vascular SMCs are crucial to atherogenesis. 54 In the present study, SMCs displayed strong expression of VAP-1/SSAO, which was also found in a previous report. 76 During differentiation of SMC, the mRNA expression, the protein expression, and the VAP-1/SSAO activity increase significantly. 77 Mercier et al have demonstrated that VAP-1/SSAO-deficient mice had larger arterial diameters, suggesting a role of VAP-1/SSAO in arterial wall remodeling.
78 MMP-9, with its proteolytic activity, is a key molecule in SMC migration and vessel remodeling. 51, 52 In the literature, intracellular ROS can also regulate the migratory and proliferative activities of SMC, aside from various inflammatory cytokines and growth factors. [79] [80] [81] ROS participate in promigratory signaling pathways, such as lamellipodia formation, actin cytoskeleton remodeling, focal adhesion turnover, and contraction of the cell body. 80 ROS also promote SMC proliferation and modulate the activity and gene expression of MMP. 81 In the present study, VAP-1/SSAO inhibition decreased MMP-9 expression in the aorta (Fig 4, F, and Supplementary Fig S2) , reduced ROS production in A7r5 hSSAO/VAP-1 SMCs (Fig 6, D) , and attenuated the migratory and proliferative abilities of PDGF-BB-treated A7r5 hSSAO/VAP-1 SMCs (Fig 6, E and F) . Moreover, we have demonstrated that inhibition of oxidative stress by NAC suppressed the proliferation and the migration of SMCs (Fig 6, E and F) . Taken together, our findings indicate that VAP-1/SSAO inhibition can regulate proliferation and migration of SMCs, directly or indirectly, via its effect on MMP-9 expression and intracellular redox state.
In the present study, we found that VAP-1/SSAO inhibition by PXS-4728A reduced atherosclerosis. However, the findings are different from the 2 reported studies; both studies used semicarbazide to inhibit VAP-1/SSAO in LDL receptor knockout mice on Western-type diet. 26, 27 When semicarbazide was given after introducing Westerntype diet for 6 or 9 weeks, collagen content and cap thickness of the plaques increased and a phenotypic switch of SMCs was induced, but regression of the atherosclerotic lesions did not result. 26 By contrast, when semicarbazide was given along with Western-type diet, an increase in the size of atherosclerotic lesions resulted. 27 One of the potential reasons for the discrepant findings is the off-target effects of semicarbazide. Semicarbazide is not a specific inhibitor for VAP-1/SSAO and can act on other enzymes involved in atherogenesis. 29, 30 For instance, semicarbazide can inhibit LOX, another amine oxidase involved in extracellular matrix maturation and proliferation, as well as SMC migration. The disturbance of LOX expression could contribute to endothelial dysfunction and plaque progression. 31 In addition, semicarbazide can also inhibit S1P lyase, 29 a key regulator of S1P signaling. S1P has diverse effects on a variety of cell types in atherogenesis, including attachment and migration of monocytes, SMC proliferation, and production of proinflammatory cytokines. 32, 33 Thus, disturbance of S1P signaling may have pro-or antiatherogenic effects, depending on the cell and the animal model studied. 34 By contrast, we used a potent and highly specific VAP-1/SSAO inhibitor, PXS-4728A, which has more than 500-fold selectivity for VAP-1/SSAO over all the related human amine oxidases (including LOX) or over 100 different macromolecular targets. 35 Therefore, off-target effects are minimized in the present study.
The present study is limited in that the human study measured plasma VAP-1/SSAO protein concentrations alone, rather than plasma VAP-1/SSAO protein concentrations and VAP-1/SSAO activity. However, serum VAP-1/SSAO protein concentrations have been shown to correlate well with serum VAP-1/SSAO activity, 22, 37 and treatment with antibody against VAP-1 can reduce more than 95% of serum VAP-1/SSAO activity. 37 Therefore, it is reasonable to speculate that subjects with CAD in the present study not only have elevated plasma VAP-1/SSAO protein concentrations but also have higher plasma VAP-1/SSAO activity. Besides, there was a marked male predominance in subjects with CAD, which may result from chance because we recruited study subjects consecutively and did not select them by gender. Because the relationship between plasma VAP-1 and the presence or the extent of CAD was similar after adjustment for gender, this limitation has limited effect on our findings.
In conclusion, plasma VAP-1/SSAO concentrations are associated with CAD in humans and can be used as a novel biomarker for assessing the presence and the extent of CAD. PXS-4728A, a specific VAP-1/SSAO inhibitor, can reduce atherosclerosis in cholesterol-fed ApoEdeficient mice through suppression of many key steps for atherosclerosis, including ROS generation, endothelial dysfunction, adhesion and transmigration of monocytes, recruitment and activation of macrophages, as well as migration and proliferation of SMCs. Our data suggest that VAP-1/SSAO inhibition is a potential treatment for atherosclerotic cardiovascular disease.
